Biotica to present at the EASL International Liver Congress 2011 in Berlin

Cambridge, UK 9 March 2011

Biotica, the leader in discovery of polyketide therapeutics, today announces that it is presenting data from its nPT-CyP cyclophilin inhibitor programme at the EASL International Liver Congress in Berlin on the 1^st April 2011.  The poster presentation, titled “Preclinical Characterization of Novel Cyclophilin Inhibitors Based on the Polyketide, Sanglifehrin” (abstract 206) will be the first public presentation of data on novel antivirals in the nPT-CyP series.

The nPT-CyP series is based on sanglifehrin, a polyketide with a naturally high affinity to CyP, to which Biotica has applied its novoPT™ technology to generate improved proprietary compounds. This series includes compounds that are:

• Highly active, with EC50s of less than 50nM in the replicon system (an in vitro assay for anti-HCV activity)
• Highly selective, with selectivity indexes (CC50/EC50) of over 1000
• Orally bioavailable
• Active against other viruses which use cyclophilin in their replication cycle (including EC50s against HIV and

    HBV of <100nM)

The profound antiviral activity and improved selectivity differentiates sanglifehrin analogues from cyclosporine-based cyclophilin inhibitors. These compounds are currently undergoing further profiling to enable selection of a candidate drug, in preparation for clinical development.

Biotica is also pleased to announce publication of a manuscript titled “Preclinical characterisation of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family” in the journal Antimicrobial Agents and Chemotherapy (AAC). Further details can be found on the AAC website.

For enquiries or to arrange to meet the Biotica delegation at EASL, please contact Caroline Phipps (.(JavaScript must be enabled to view this email address)).